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CONTEXT AND CAVEATS 
At present, there are no effective prognostic tools to guide adjuvant therapy based 
on response to neoadjuvant chemotherapy for locally advanced breast cancer 
(LABC). In the current study, a comprehensive clinico-pathological evaluation of a 
cohort of patients from a single centre was reviewed, including paired pre-
chemotherapy diagnostic tumour core biopsy and post-chemotherapy surgical 
specimens, and a new clinico-pathological response index (NPRI) was developed.  
Patients can be divided into four distinct prognostic groups based on disease free 
survival (DFS) and breast cancer specific survival (BCSS), and the index was 
validated in an internal and external independent cohorts. 
Patients with higher NPRI scores showed statistically significant associations with 
shorter DFS and BCSS. The specificity and sensitivity of NRPI is superior to 
currently used indexes including pathological complete response (pCR), residual 
cancer burden and pathological TNM staging (yp-TNM).  For example, the good 
prognosis groups included 52% of all patients based on NPRI scores, compared to 
only 15% of patients by using the pCR criteria. This score has the potential to 
become the best prognostic tool currently to determine adjuvant-therapy following 
neoadjuvant chemotherapy, and to standardized important factors for the reporting of 
results in this setting.  However, the NPRI has to be tested as a clinical tool to guide, 
and make a difference to, the choice and outcome of adjuvant-therapy in a 
prospective clinical trial. 
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Abstract  
Purpose: There is a need to identify more sensitive clinico-pathological criteria to 
assess the response to Neo-ACT and guide subsequent adjuvant-therapy.  
Experimental Design: We performed a clinico-pathological assessment of 427 
patients who had completed Neo-ACT for locally advanced breast cancer (LABC) 
with a median follow-up of 5-years. Patients were divided into a training set treated 
with anthracycline combination chemotherapy (AC, n=172); an internal validation set 
treated with AC and taxane (n=130); and an external validation set treated with AC 
with or without taxane (n=125).  
Results: A multivariate Cox regression model demonstrated the absence of fibrosis, 
presence of lympho-vascular invasion, and increasing number of lymph node 
metastases were significantly associated with short disease-free survival (DFS) and 
breast-cancer specific survival (BCSS, p<0.01), whilst reduction of tumour size was 
associated with DFS (p=0.022). Nottingham Clinico-Pathological Response Indexes 
(NPRIs) were calculated and four prognostic groups (NPRI-PGs) were identified.  
Patients in prognostic group 2 (NPRI-PG2) for DFS (n=63/172; 36.6%) and BCSS 
(66/172; 38.4%) have the same prognosis as those who achieved pCR (NPRI-PG1; 
15%). Receiver operating characteristic (ROC) curves indicated that the NPRI 
outperformed the currently used prognostic factors and adding NPRI improved their 
performance as a predictor for both DFS (AUC=0.87) and BCSS (AUC= 0.88).  
Conclusions: The NPRI predicts DFS and BCSS, with a higher sensitivity than pCR. 
The NPRI can also improve the sensitivity and specificity of clinico-pathological 
response as a study end-point, for assessing response to Neo-ACT, and can serve 
as a valuable tool for the discovery of future predictive molecular markers. 
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Introduction 
A meta-analysis combining data from over 3,900 patients1 with locally advanced 
breast cancer (LABC) demonstrated no difference in overall survival and disease 
progression between neoadjuvant and adjuvant chemotherapy.  Several clinical trials 
have confirmed the safety and efficacy of neoadjuvant chemotherapy and 
established its utility in the management of LABC2.  Although response to 
neoadjuvant chemotherapy may provide some indication about the potential 
response of the tumour to further treatment3, and may be informative about cancer 
biology4, the optimal method of assessing response and it impact on survival is yet to 
be established and there are no universally accepted criteria5.   
Many studies have shown that achieving pathological complete response (pCR) after 
neoadjuvant chemotherapy predicts overall survival, which is independent of 
treatment regimen6-8. However, selected trials comparing different neoadjuvant 
chemotherapy regimens have failed to demonstrate an association between pCR 
rate and improved outcome9.   Furthermore pCR is an imperfect surrogate for clinical 
outcome, given that: i) only a small fraction of neoadjuvant chemotherapy patients 
achieve pCR (3-28%; according to the definition of pCR and chemotherapeutic 
regimen), ii) patients who do not achieve pCR may still have a good prognosis whilst 
patients who achieve pCR can still experience recurrent disease10, and iii) the 
presence of residual cancer cells observed after neoadjuvant therapy reflects a wide 
range of responses from near-pCR to  complete resistance. 
In this study we identified clinico-pathological criteria that could assess and grade 
response to neoadjuvant chemotherapy and subsequently correlate with clinical 
outcome.  We used these criteria to develop a new clinico-pathological response 
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index (the Nottingham Clinico-Pathological Response Index, NPRI) that can predict 
the clinical outcome for patients who receive neoadjuvant chemotherapy.  
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Materials and Methods 
Patients 
427 patients with clinical stage IIA-IIIC disease (T1-4, N0-3, and M0) who completed 
neoadjuvant chemotherapy for LABC were included in this study and divided into 3 
cohorts according to treatment centre and regimen:   
1) The training cohort (n=172) were diagnosed at Nottingham University 
Hospitals (NUH) between 1996 and 2011 and treated with standard 
anthracycline regimens (AC) in the form of 6 cycles of FEC (5-fluorouracil  
500 mg/m2, epirubicin 75–100 mg/m2, cyclophosphamide 500 mg/m2, on day 
1 of a 21-day cycle).  This cohort was used to characterize the NPRI and to 
determine cut-off points for prognostic groups (NPRI-PGs) based on DFS and 
BCSS.   
2) The internal validation cohort (n=130) included patients who were treated at 
the same institution (NUH) between 2002 and 2011 and received a taxane in 
addition to the AC regimens (AC-T) as part of clinical trial protocols.  
3) The external validation cohort (n=125) were treated at the Breast Clinical 
Trials Unit at Mount Hospital (Perth, Western Australia) between 1999 and 
2011 and received AC regimens with or without a taxane.   
Detailed patient demographics and clinico-pathological characteristics were 
prospectively assessed and regularly updated (summarized in supplementary online 
table S1).  All patients underwent neoadjuvant chemotherapy, mastectomy or breast-
conserving surgery and axillary dissection, followed by adjuvant radiation therapy. 
Patients with hormone receptor–positive breast cancer were offered 5 years of 
adjuvant endocrine therapy.  The median follow-up time was 60 months for the entire 
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population and all patients gave their informed consent before initiation of therapy. 
The Nottingham Research Ethics Committee approved this work. 
Pathological Review 
Six authors (IOE, SEP, AHSL, BL, DP and TM A-F) contributed to a comprehensive 
review of the pathology reports and haematoxylin and eosin stained slides from pair-
matched diagnostic core biopsies and surgical resection specimens (breast and 
regional lymph nodes). Pathological features were assessed and their evaluation 
criteria are summarized in supplementary online table (S2).  Absence of fibrosis with 
or without granulation tissue, and necrosis in both the tumour bed and dissected 
regional lymph nodes, was considered as evidence for the absence of any 
pathological response reaction to chemotherapy.  pCR was defined as the absence 
of residual invasive carcinoma in both the breast and regional lymph nodes. The 
number of histologically positive lymph nodes was determined by examination of 
serial macroscopic sections of each lymph node. On average, 16 breast-blocks and 
all submitted lymph nodes were examined for each case before a diagnosis of pCR 
was reached. 
Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth 
factor receptor 2 (HER2) measurements were available for all patients and re-
assessed according to the most recent American Society of Clinical 
Oncology/College of American Pathologists (ASCO/CAP) guidelines14,15. The 
primary tumour size and lymph node stage at the time of diagnosis were determined 
by physical examination and imaging, including mammography and sonography.  
Clinical staging of the breast cancer at the time of diagnosis (presenting-TNM stage) 
and the pathological staging after neoadjuvant chemotherapy (yp-TNM stage) were 
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determined using the revised American Joint Committee on Cancer (y-AJCC) 
staging system for breast cancer16.   
Residual cancer burden   
Residual cancer burden (RCB) was estimated from routine pathologic sections of the 
primary breast tumour site and the regional lymph nodes after completion of 
neoadjuvant chemotherapy according to the MD Anderson Cancer Centre criteria4. A 
calculated RCB index for each patient was generated using the calculation formula 
at the MD Anderson Cancer Centre’s website 
(http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3) (last 
accessed 19th June 2014).    
Detailed statistical methods  
Statistical analyses were performed using STATISTICA (Stat Soft Ltd, Tulsa, USA) 
and SPSS (version 17, Chicago, USA).  Where appropriate, Pearson’s chi-squared; 
student’s t-test and ANOVA tests were used. All tests were two-sided with a 95% 
confidence interval (CI) and a p value of less than 0.05 was considered to be 
indicative of statistical significance.  Cumulative survival probabilities and 5-year 
DFS were estimated using the univariate Cox models and the Kaplan–Meier plot 
method where appropriate, and differences between survival rates were tested for 
significance using the log-rank test.  
Development and calculation of NPRI scores 
After definition of factors that were associated with DFS and BCSS, multivariate Cox 
proportional hazards models (with backward stepwise exclusion of these factors, 
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using a criterion of p <0.05 for retention of factors in the model) were used to identify 
factors that were independently associated with clinical outcomes.  The statistical 
significance of the model was assessed based on the likelihood ratio test. The 
proportional hazards assumption was tested using both standard log-log plots and by 
generating Kaplan–Meier survival estimate curves, and observing that the curves did 
not intersect with each other. Hazard ratios (HRs) for relapse and death risks and 
95% confidence intervals were calculated from the Cox proportional hazards 
analysis.  Subsequently, NPRI scores for both DFS and BCSS were calculated using 
the summations of β-coefficient values of the factors/measurements retained in the 
final model after controlling for both hormonal and chemotherapies. 
Determination of NPRI cut-off 
As an NPRI score is a continuous risk, to evaluate its efficiency as a prognostic tool 
we defined pathological response subgroups associated with a prognostic outcome 
using specific cut-offs.  We determined thresholds to define four NPRI prognostic 
groups (NPRI-PGs) with distinct prognoses: NPRI-PG1 included those with no traces 
of residual disease (i.e. those who achieved pCR), NPRI-PG2 included those with 
good response (near-pCR) and NPRI-PG3 and NPRI-PG4 those with moderate and 
the poorest responses respectively. To determine the first cut-off point (between 
NPRI-PG4 and other NPRI score groups), a multivariate Cox regression model was 
used that included the clinical and demographic covariates and a dichotomous NPRI 
based on cut-off points selected between the 5% and the 95% quartiles of the NPRI 
score distribution. The optimal cut-off point was selected as the quartile that 
maximized the profile log-likelihood of this model. A second cut-off point (between 
NPRI-PG2 and NPRI-PG3) was determined similarly by maximizing the profile log-
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likelihood of a Cox model that included all clinical covariates and the first 
dichotomous PRI-score factor (i.e. NPRI-PG4 versus NPRI-PG2/3).  
Clinical impact of NPRI and model discrimination 
To assess the potential clinical impact of the NPRI, multivariable analyses using the 
Cox proportional hazards model were performed with the NPRI score as a 
continuous variable, and/or a prognostic set of clinical-pathological variables 
controlling for neoadjuvant chemotherapy regimen and adjuvant chemotherapy.  
Receiver operating characteristic (ROC) curves were generated to compare the 
different prognostic models with or without inclusion of NPRI scores. Logistic fit of 
low versus high survival category by cumulative hazard (the product of the hazard 
ratios of each incorporated variable) was performed.  Area under the curve (AUC) 
values was calculated from ROC curves.  An AUC of 0.8 or above was considered a 
good classifier. 
Model discrimination was evaluated based on Harrell's concordance index (c index), 
which is a generalized area under the receiver operating curve (AUC) for censored 
observations and is equal to the probability of concordance between the predicted 
probability of relapse and the relapse outcome17. The c index was adjusted for bias 
using bootstrap resampling with 300 replications. The CI for the c index was 
obtained based on approximate normality using the variance estimate of the 
unadjusted index.  
Fitted polynomial function curves were calculated which summarise the broad 
relativity between the NPRI value and both 5- and 10-year DFS and BCSS.  Fitted 
polynomial curves were constructed from the raw data by applying median DFS and 
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BCSS of each NPRI-PG against the 5 and 10 year DFS and BCSS for each division.  
Predictions from the curves were compared with the actual values. 
Predictive accuracy of NPRI compared with other prognostic clinico-
pathological factors 
To evaluate whether the NPRI-PGs add new independent prognostic information to 
the revised y-AJCC stage, pCR or residual cancer burden (RCB), we performed 
separate Kaplan-Meier analyses by NPRI prognostic group within each AJCC stage 
stratum, RCB classes and non-pCR subgroup. The significance of the additional 
stratification provided by the NPRI was evaluated based on the log-rank test.  
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Results 
Clinico-pathological factors associated with higher risk of relapse and death after 
FEC chemotherapy in univariate Cox analysis included absence of fibrosis in primary 
tumour site and regional lymph nodes, presence of lymphovascular invasion (LVI), 
and increasing number of lymph node metastases. These factors maintained 
significance as independent predictors for both DFS and BSSS after controlling for 
adjuvant chemotherapy and other covariates by using multivariate Cox proportional 
hazards models with backward stepwise exclusion.  The percentage of reduction in 
primary tumour size showed statistical significant association with DFS only (Table 1, 
supplementary table S3, figure S1).  None of the covariates exhibited significant 
deviations from the proportionality assumption or had time-dependent effects (code 
system used is summarized in supplementary table S4). Subsequently, the 
summations of β coefficient values produced by the Cox analysis were used to 
calculate the NPRIs for each patient as follows: 
NPRI for DFS (NPRIDFS) =  
Fibrosis status (0, 1) x 1.2830 + LVI status (0, 1) x 0.8431 + number of positive 
lymph nodes (0-43) x 0.0537 + percentage of reduction of primary tumour size 
(+100% to -100%) x -0.008162 + planned hormonal therapy status (0, 1) x -0.7521 
NPRI for BCSS: (NPRIBCSS) =  
Fibrosis status (0, 1) x 1.618028 + LVI status (0, 1) x 1.048666 + number of positive 
lymph nodes (0-43) x 0.063750 + planed hormonal therapy status (0, 1) x -1.093202 
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The prognostic value of the NPRI compared with prognostic pathological and 
clinical factors 
We examined the predictive accuracy of the NPRI score compared with other 
prognostic clinico-pathological factors by performing the Cox proportional hazards 
univariate and multivariable analyses controlling for neoadjuvant and adjuvant 
chemotherapy. In the training cohort, patients had almost a three-fold increase in 
both relapse (HR 2.83; 95% CI, 2.17 to 3.68; p = 1.1x 10-14) and death (HR 2.72; 
95% CI, 2.02 to 3.66; p = 4.6x 10-11) for each unit of increase in the NPRI 
(supplementary table S3).  When the NPRI was included in a multivariate Cox 
regression model (Figures 1-A and supplementary S2-A), the overall predictive 
power of the model was significantly improved for both DFS (p = 3.79x10-13) and 
BCSS (p = 3.6x10-9), and the NPRI was significantly associated with a two-fold 
increase of the risk of disease recurrence (HR 2.07; 95% CI, 1.36 to 3.16; p = 0.001) 
and death (HR 2.14; 95% CI, 1.37 to 3.36; p = 0.001). 
Using univariate analysis, a similar statistically significant association between NPRI 
and both DFS and BCSS was found in both the internal and external validation 
cohorts (Supplementary table S3).  When the Cox proportional hazards multivariable 
analysis was repeated in the two validation sets controlling for neoadjuvant and 
adjuvant chemotherapy, the NPRI score outperformed other pathological and clinical 
covariates and was associated with both DFS and BCSS. All other pathological and 
clinical covariates failed to show a consistent association with prognosis (Figures 1, 
B&C and S2 B&C).   
To assess the contribution of the NPRI toward prediction of response to neoadjuvant 
chemotherapy, Cox proportional hazards statistical models containing relevant 
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pathological and clinical predictors controlling for neoadjuvant and adjuvant 
chemotherapy were constructed. ROC analyses were performed as follows:  
1. RCB score alone. 
2. NPRI score alone. 
3. A prognostic model including RCB score, yp-TNM, c-TNM, histological grade, 
HER2, ER, pCR status, age, neoadjuvant and adjuvant chemotherapy without 
NPRI score. 
4. The same prognostic model with NPRI scores.   
This demonstrated AUC values for DFS of 0.77, 0.85, 0.82 and 0.87 for 1, 2, 3, and 
4 respectively (Figure 2-A). AUC values for BCSS were 0.71, 0.85, 0.84 and 0.88 
respectively (Supplementary figure S3-A).  These results remained consistent when 
the analysis was repeated for both internal (Figure 2-B and supplementary figure S3-
B) and external validation cohorts (Figure 2-C and supplementary figure S3-C). 
NPRI identifies distinct prognostic groups of none-pCR patients 
We identified two cut-off points to assign patients with residual disease (non-pCR; or 
non NPRI-PG1) after FEC treatment into one of three classes: NPRI-PG2 (good 
prognosis group), NPRI-PG3 (moderate prognostic group), and NPRI-PG4 (poor 
prognostic group).  The first cut-off point (NPRI-PG4 v NPRI-PG2/3) was selected as 
the 83th percentile (NPRI, 0.91021), and as the 92th percentile (NPRI, 1.87383) for 
DFS and BCSS, respectively.  The second cut-off point (NPRI-PG2 v NPRI-PG3) 
corresponds to the 64.5th percentile (NPRI, 0.522257) and to the 53.5th percentile 
(NPRI, 0.01921) for DFS and BCSS, respectively.  The cut-off points defined 
subgroups of NPRI-PG1 to NPRI-PG4 with increasingly poor prognosis (Figure 3). 
 16 
The cumulative incidence estimate of the overall probability of relapse within 5 years 
was 9% for the pCR group (NPRI PG1) and 13% for NPRI-PG2, whereas it was 44% 
and 86% for NPRI-PG3 and NPRI-PG4, respectively.  Similarly, the cumulative 
incidence estimate of the overall probability of death within 5 years was 4% for the 
pCR group (NPRI PG1) and 5% for NPRI-PG2, whereas it was 33% and 71% for 
NPRI-PG3 and NPRI-PG4, respectively.   
Applicability of the NPRI was evaluated in both the internal and the external 
independent cohorts.  In both cohorts, NPRI defined groups with increasingly poor 5-
year prognoses (Figures 3-B&C).  The separation of both the 5-year relapse and 
death rates were somewhat smaller in the training set than for the internal validation 
cohort. To explore this furthermore, we combined the poor prognosis groups 
together (NPRI-PG4 and NPRI-PG3) and compared the 5-year DFS and BCSS with 
those in the NPRI-PG1 (pCR patients) and found the separation of both the 5-year 
relapse and death rates were still wider in AC-T cohort vs. FEC-only cohort (21% for 
DFS and 12% for BCSS).  The c-index of the prognostic model on the internal and 
external validation cohorts was 0.776 (95% CI, 0.67 to 0.87) and 0.841 (95% CI, 
0.76 to 0.92).  
The Pearson correlation coefficient and fitted polynomial function curves showed that 
there is an excellent inverse linear correlation between NPRI and both DFS and 
BCSS.  In figure 5, the fitted polynomial function summarises a broad relationship 
between the NPRI value and median 5- and 10-year survival. 
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NPRI prognostic groups stratify clinical outcome of breast cancer molecular 
sub-groups 
Subgroup analysis of whole patients confirmed that NPRI is a valid prognostic tool 
regardless of molecular classes of breast cancer (Figure 4-A-D).  Applying the NPRI 
to the ER positive subgroup demonstrated that 45% of patients might have poor 
clinical outcome despite receiving adjuvant hormone therapy after completing 
neoadjuvant chemotherapy, whilst 38% of ER negative cancers had an excellent 
prognosis. Moreover, only 58% of HER2 overexpression/amplification breast cancers 
had a favourable outcome despite receiving Herceptin following neoadjuvant 
therapy.  Although patients with triple negative breast cancer did not receive targeted 
adjuvant therapy after neoadjuvant therapy, our results demonstrated that 42% of 
those patients had excellent prognosis. 
The NPRI prognostic groups stratify prognoses of TNM stages 
Subgroup analyses of the TNM stage at diagnosis also confirmed the prognostic 
power of the NPRI to separate clinical TNM stage III cancers into distinct DFS (p= 
2.6 x 10 -15, Figure 4-E) and BCSS prognostic groups (p=4.5 x 10 -11; data not 
shown).  Results demonstrated that 41% of those patients achieved excellent 
prognosis.   
In addition we evaluated the contribution of the NPRI prognostic group to the 
prognostic power of each post-therapy yp-TNM stage group (Figure 4-F-G).  
Regarding DFS and BCSS, NPRI classified both yp-TNM stage II and stage III 
patients into three distinct prognostic subgroups (ps<0.001; Figure 4-F-G). 
Therefore, NPRI classification appears to add significant prognostic power compared 
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with post-treatment pathologic y-AJCC stage, at least for stage II/III tumours that 
represent 2/3 of our patients. 
The NPRI adds significant prognostic power compared with Residual Cancer 
Burden classes 
By application of the NPRI to residual cancer burden (RCB) classes in all patients 
after pooling three cohorts together; the NPRI improved the prognostic stratification 
of patients who were designated as RCB classes II (n=195; predicted to have a 5-
year DFS and BCSS of 67% and 78%, respectively) and III (n=110; predicted to 
have a 5-year DFS and BCSS of 46% and 63%, respectively). Each class has been 
stratified into 3 distinctive prognostic groups (Figure 4-H-I, ps<0.0001)).  Application 
of NPRI to RCB class II and III, showed that 17% of those patients actually 
experienced excellent prognosis and 17% of RCB class II had a worse prognosis 
than that predicted for that class of patients.  
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Discussion 
Up to 20% of breast cancer patients present with locally advanced disease which is 
associated with a poor prognosis15.  In those tumours that lack a specific therapeutic 
target (i.e. ER or HER2), conventional chemotherapy remains the mainstay of 
systemic therapy.  Knowledge of the primary tumour’s sensitivity or resistance to 
neoadjuvant chemotherapy can predict the efficacy of these agents on micro-
metastatic disease. This information can be used to tailor adjuvant therapy after 
definitive surgery4. However, at the present, there are no effective prognostic tools to 
guide adjuvant therapy based on response to neoadjuvant chemotherapy.  Although 
the pathological evaluation of tumour response is still the gold standard, the lack of 
uniform reporting of pathological response remains a problem16. 
In this study, a comprehensive clinico-pathological evaluation of a cohort of patients 
who received neoadjuvant AC/FEC chemotherapy at a single centre was conducted 
and the NPRI was developed, which was then validated in two independent cohorts.  
Patients with higher NPRI scores showed statistically significant associations with 
shorter DFS and BCSS. The NPRI can categorise patients into four prognostic 
groups (NPRI-PG1 to PG4) with patients in NPRI-PG2 having the same 5-year 
outcome as those with pCR (NPRI-PG1), irrespective of the type of neoadjuvant 
chemotherapy administered, ER status, or the pathological stage of residual disease. 
The prognostic information described herein represents the most detailed data 
available on DFS and BCSS outcomes for patients treated with neoadjuvant 
chemotherapy.  The NPRI outperforms other traditional predictors of clinical outcome 
of breast cancer such as residual cancer burden, pCR and the revised yp-TNM 
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stage, with high predictive accuracy in the training cohort and in the two independent 
validation sets.   
Application of the NPRI can be used to tailor adjuvant treatment for patients with 
locally advanced breast cancer.  For example, the NPRI identifies a second good 
prognostic group (NPRI-PG2) that have responded as well as the cohort with pCR 
(PG1) and can be spared further multiple cycles of unnecessary (and potentially 
toxic) treatments. Likewise, NPRI-PG3 and PG4 of ER positive patients had a 
moderate to poor prognosis despite receiving adjuvant hormone therapy after 
completing neoadjuvant chemotherapy.  Therefore, the NPRI identifies an important 
subset of patients with combined insensitivity to chemo- and hormone therapies that 
may benefit from novel therapy in a trial setting.   
The separation of the 5-year relapse and death rates were somewhat better in 
patients who received AC+T chemotherapy compared with those who received AC 
only, indicating some benefit from the addition of a taxane.  But this is uncertain due 
to the lower number of patients in the NPRI-PG4 subgroup.  However; after 
combining NPRI-PG3 and NPRI-PG4 we found the same separation, confirming that 
those patients might benefit from adding a taxane to anthracycline chemotherapy, in 
agreement with some published clinical trials17.  Moreover, the c-index of the 
prognostic model on the internal and external validation cohorts showed similar 
sensitivity and specificity. 
It has been recommended that the predictive ability of a new score should be 
evaluated based on whether the score improves an already optimized multivariate 
model of available risk factors18.  Based on this, a statistical prognostic model, 
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including an NPRI score and known prognostic factors, has shown to be superior to 
all the prognostic models without the NPRI.  
Several studies have attempted to provide criteria for response after neoadjuvant 
chemotherapy16 by using clinical, MRI or sonography findings19,20 or by bi-
dimensional measurement of the primary tumour bed in resection specimens3,16.   In 
fact, these systems have incorporated macro-anatomical features of breast cancer 
(viz. residual tumour size and lymph node status].   The NPRI, with inclusion of 
lymphovascular invasion, host response and changes in tumour size, highlights also 
the importance of the tumour micro environment as a predictor for response to 
chemotherapy.   
In agreement with other studies3,21,22 we found lymph node status after neoadjuvant 
chemotherapy is still the single most important prognostic factor. However, the 
increasing use of sentinel lymph node biopsy either before or after neoadjuvant 
chemotherapy leads to difficulties in evaluating the prognostic importance of lymph 
node status. With regard to the interpretation of sentinel lymph node status after 
neoadjuvant chemotherapy, the current data is inconsistent and requires further 
evaluation23. However, it is possible that with adequate standardization of the 
techniques and data from prospective clinical trials, sentinel lymph node status after 
neoadjuvant chemotherapy could be added to our index for patient selection to 
reduce surgical morbidity in the good prognostic groups.    
In our study, the presence of lymphovascular invasion after neoadjuvant 
chemotherapy was an independent predictor of clinical outcomes, in agreement with 
previous studies24,25.  It has been shown that tumour emboli in vascular spaces are 
relatively resistant to treatment when compared to carcinoma invading the stroma26. 
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It should be noted that the identification of lymphovascular invasion may sometimes 
be difficult as the residual tumour nests or DCIS may show marked retraction 
artefact in the fibrous stroma mimicking invasion5.  Thus, proper tissue fixation and 
immunohistochemical staining for lymphatic channel markers may be useful to 
distinguish tissue retraction from lymphatic invasion.  
Although residual tumour size has been proposed as a prognostic factor for breast 
cancer10,25, we found the reduction in primary tumour size was more predictive of 
DFS than actual residual tumour size after neoadjuvant chemotherapy. In fact, using 
residual tumour size does not discriminate between large contiguous carcinomas 
(which have shown minimal treatment effect) with microscopic foci scattered in a 
tumour bed with equally great dimensions (demonstrating significant treatment 
effect).  Many examinations have been proposed to monitor the extent of the residual 
disease extent during neoadjuvant chemotherapy, such as physical examination, 
mammography and sonography, but most studies demonstrate modest accuracy 
when compared with final pathological assessment27.  More recently, there is 
increasing evidence that magnetic resonance imaging (MRI) is an excellent imaging 
tool with high specificity rate for both early response monitoring and the assessment 
of  the extent of residual disease28. However, relatively few studies reported direct 
comparisons between MRI and other cost-effective tests28.  Partridge et al29 found 
that MRI tumour volume was more predictive of DFS than tumour diameter, 
suggesting that volumetric changes measured using MRI may provide a more 
sensitive assessment of treatment efficacy.  Furthermore, changes of metabolic 
volume measured by functional MRI could reflect early outcomes of neoadjuvant 
chemotherapy30.  In fact, future incorporation of MRI results into the NPRI score 
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could add another dimension to NPRI for early assessment of response to 
neoadjuvant chemotherapy even before completion of the full course.   
Limitations of the study and future directions 
Although we validated our findings in two independent cohorts and we have shown 
that the NPRI can supplement existing methods to define pathologic response, the 
utility of the NPRI requires further validation in larger patient populations. It would 
require prospective evaluation to demonstrate its role as a prognostic tool and 
potentially to select patients for novel systemic therapies following neoadjuvant 
chemotherapy.  In addition, further studies are needed to address inter-observer 
variability, standardization of NPRI measurements and develop a more objective 
methodology to quantify such factors as fibrosis, lymphovascular invasion and 
changes in tumour size. Further refinement of the scoring system through the 
addition of new molecular or biologic markers is also needed. 
Conclusion 
We suggest that the incorporation of the NPRI in assessing tumour response 
following neoadjuvant chemotherapy, will aid in individualising systemic treatment in 
patients with locally advanced breast cancer, in order to optimize patient outcomes.  
In particular, it may identify patients who fail to benefit from standard chemotherapy 
regimens, such that further treatment with novel therapies is warranted. We believe 
that this scoring system may provide a standardized approach to reporting the 
tumour response to neoadjuvant chemotherapy. 
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Abbreviations 
AC = Anthracycline and Cyclophosphamide combination 
AC-T = Anthracycline and Cyclophosphamide combination, followed by Taxane 
AT = Adjuvant Therapy 
AUC = Area Under Curve 
BC = Breast Cancer 
BCSS = Breast Cancer Specific Survival 
CI = Confidence Interval 
DCIS = Ductal Carcinoma in Situ 
DFS = Disease Free survival 
DP = Disease Progression 
ER = Oestrogen Receptor 
FEC = 5-Fluorouracil (5-FU) 500 mg/m2, Epirubicin 75–100 mg/m2, Cyclophosphamide 500 
mg/m2, on day 1 of a 21-day cycle. 
HER2 = Human Epidermal Receptor 2 
inv-CA size = Residual invasive size 
LABC = Locally Advanced Breast Cancer 
LN = Lymph node 
LVI = Lympho-vascular Invasion 
Neo-ACT = Neoadjuvant chemotherapy  
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OS = Overall Survival 
NPRI = Nottingham clinico-Pathological Response Index 
NUH = Nottingham University Hospitals Trust 
PER-BC = Primary Oestrogen Receptor Negative Breast Cancer 
pCR = Pathological Complete Response (Primary and Lymph nodes are negative) 
pre-PTS = pre-chemo Patient Tumour Size (maximum diameter) 
PGs = Prognostic Groups 
PTS = Patient Tumour Size (maximum diameter) 
RCB = Residual Cancer Burden 
RD = Residual Disease 
ROC = Receiver Operating Characteristic curves 
RT = Residual Tumour 
SLN = Sentinel Lymph node 
T = Taxane 
c-TNM = Clinical TMA stage  
yp-TNM = revised pathological TNM stage 
% CA = Percentage of overall cancer cellularity 
% CIS = Percentage of cancer that is residual intra-ductal carcinoma 
% inv-CA = Percentage of invasive component 
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% cp-PTS-R = Percentage of the clinico-pathological tumour size reduction
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Table (1): Univariate and multivariate backward step-wise analysis for factors associated with disease 
free survival (DFS) in the training cohort. 
Risk Factors 
Univariate analysis Multivariate analysis  
HR 95% CI p HR 95% CI p 
Age (continuous variable) 1.03 1.01 1.06 0.005 
    Hormonal therapy (Yes, No) 0.74 0.43 1.26 0.265 0.45 0.25 0.81 0.008 
Adjuvant Chemotherapy (Yes, No) 1.56 0.89 2.74 0.118 
    Presenting clinical tumour size  1.01 1.00 1.02 0.003 
    Presenting histological grade (High) 0.91 0.53 1.57 0.744 
    Tumour type other than IDC-NST 1.47 0.76 2.86 0.253 
    ER expression (negative)  1.05 0.62 1.80 0.852 
    HER2 status (overexpression) 0.76 0.37 1.57 0.463 
    PR expression (negative)  0.94 0.51 1.72 0.837 
    Triple negative phenotype (Yes, No) 0.96 0.54 1.71 0.894 
    Pathological TNM (yp TNM) 
 Stage 0 
 Stage I 
 Stage II 
 Stage III 
1.00 
0.78 
3.41 
7.05 
0.13 
1.00 
2.15 
4.67 
11.6 
23.1 
1.3x10-4 
    Residual inv CA size 1.02 1.01 1.02 1.5x10-5 
    Tumour size reduction 0.26 0.13 0.54 2.6x10-4 0.99 0.98 1.00 0.022 
Number of positive lymph nodes  1.06 1.03 1.09 1.6x10-4 1.05 1.01 0.09 0.013 
Percentage of residual inv CA  1.02 1.01 1.03 1.0x10-5 
    
Extension and distribution of Inv CA 
 No invasive/scattered cells 
 One focus or scattered foci 
 Nests, groups or sheets 
1.00 
2.40 
5.50 
0.93 
5.51 
6.33 
14.55 
4.6x10--4 
    Absence of fibrosis 4.14 2.40 7.16 4.0x10-7 3.65 2.07 6.45 8.0x10-6 
Presence of LVI 3.04 1.77 5.23 6x10-5 2.17 1.20 3.89 0.010 
Presence of ductal carcinoma in situ 1.60 0.93 2.86 0.088 
    IDC-NS; invasive ductal carcinoma-no special type, ER; oestrogen receptor, PR; progesterone 
receptor, HER2; human epidermal receptor 2, inv-CA; invasive carcinoma, LVI; Lymphovascular 
invasion 
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Figure legends 
 
Figure 1: A-C. Multivariable Cox proportional hazards regression analyses for 
disease free survival (DFS; left panel) and corresponding forest plots (Right panel).  
Comparison of Nottingham clinico-pathological response index (NPRI) score (as 
continuous variable) with known prognostic clinico-pathological factors including: 
pathological complete response (pCR vs. non-pCR), residual cancer burden (RCB) 
score, presenting clinical TNM (Tumour, Node and Metastases) stage (II vs. III), 
revised pathological TNM stage (yp-TNM; stage 0 vs. I/II/III), histological grade 
based on Nottingham grading system (1 vs. 2/3), ER (oestrogen receptor) 
expression status (negative vs. positive), HER2 (human epidermal receptor 2) 
overexpression/amplification status (overexpression/amplification vs. no 
overexpression/amplification), adjuvant chemotherapy, adjuvant hormonal therapy, 
neoadjuvant therapy (if applicable) and age at diagnosis (≤54 vs. ≥55 years) in the 
training (A), internal validation (B) and external validation (C) cohorts. Solid squares 
represent the hazard ratio (HR) of recurrence and open-ended horizontal lines 
represent the 95% confidence intervals (CIs). All p values were calculated using Cox 
proportional hazards analysis and p < 0.05 was considered as statistical significant p 
value. AC: Anthracycline, T: Taxane, AC-T: Anthracycline and Taxane. 
 
 
 
 
Figure 2: Receiver operating characteristic (ROC) analysis of Nottingham clinico-
pathological response index (NPRI) score and other clinico-pathological covariates 
were performed for predicting disease free survival  in the training (A), internal 
validation (B) and external validation (C) cohorts.    The area under the curve (AUC) 
was calculated for ROC curves, and sensitivity and specificity was calculated to 
assess the performance of residual cancer burden (RCB) alone (1), NPRI alone (2), 
and * a statistical prognostic model that constructed based on multivariable Cox 
proportional hazards incorporating known clinico-pathological prognostic variables 
including: pathological complete response (pCR), RCB score, presenting clinical 
TNM (Tumour, Node and Metastases) stage, revised pathological TNM stage (yp-
TNM) stage, histological grade based on Nottingham grading system, ER (oestrogen 
receptor) expression status, HER2 (human epidermal receptor-2) status, and age at 
diagnosis (3). ** ROC analysis was also performed for the aforementioned 
prognostic model after incorporating the NPRI score (4).  Dashed grey lines indicate 
the 45º angle tangent line marked at a point that provides best discrimination 
between true positives and false positives, assuming that false positives and false 
negatives have similar costs. AC: Anthracycline, T: Taxane, AC-T: Anthracycline and 
Taxane. 
 
Figure 3: Kaplan Meier curves and lifetime table showing disease free survival 
(upper panel) and breast cancer specific survival (lower panel) in the training (A), 
internal validation (B), and external validation (C) cohorts stratified according to 
Nottingham clinicopathological response index- prognostic groups (NPRI-PGs). See 
text for details. AC: Anthracycline, T: Taxane, AC-T: Anthracycline and Taxane. 
 
 
 33 
Figure 4: A-D.  A-D. Kaplan Meier curves showing DFS of oestrogen receptor (ER) 
positive (A), ER-negative (B), HER2 overexpression/amplification (C) and triple 
negative (D) breast cancer patients, stratified according to NPRI- prognostic groups 
(NPRI-PGs). E. Kaplan Meier curves showing DFS of presenting clinical TNM stage 
III stratified according to NPRI-PGs.  F. Kaplan Meier curves showing DFS  of 
revised pathological TNM stage II (yp-TNM stage II; F) and yp-TNM stage III (G) 
patients stratified according to NPRI-PGs. Kaplan Meier curves showing DFS of 
residual cancer burden (RCB) class II (H) and class III (I) patients in the training 
cohort stratified according to NPRI-PGs.  See text for details. AC: Anthracycline, T: 
Taxane, AC-T: Anthracycline and Taxane. 
Figure 5: Fitted polynomial function curves and equations for disease free survival 
(DFS, A) and breast cancer specific survival (BCSS; B) summarises a broad 
relationship between the Nottingham clinicopathological response index (NPRI) 
value and median 5 (dashed line) and 10 (solid line) year survivals in the training 
cohort.   
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Supplementary online figure legends 
 
Supplementary Figure S1: Kaplan Meier curves showing disease free survival (DFS) 
in the training (upper panels), internal validation (middle panels) and external 
validation (lower panels) cohorts  stratified according to number of lymph node (LN) 
metastases (i), presence of lympho-vascular invasion (LVI; ii), absence of fibrosis 
(iii) percentage of reduction in primary tumour size  (iv). See text for details. AC: 
Anthracycline, T: Taxane, AC-T: Anthracycline and Taxane. 
 
Supplementary Figure S2: A-C. Multivariable Cox proportional hazards regression 
analyses for breast cancer specific survival (BCSS; left panel) and corresponding 
forest plots (Right panel).  Comparison of Nottingham clinico-pathological response 
index (NPRI) score (as a continuous variable) with known prognostic  clinico-
pathological factors including: pathological complete response (pCR vs. non-pCR), 
residual cancer burden (RCB) score, presenting clinical TNM (Tumour, Node and 
Metastases) stage (II vs. III), revised pathological TNM stage (yp-TNM; stage 0 vs. 
I/II/III), histological grade based on Nottingham grading system (1 vs. 2/3), ER 
(oestrogen receptor) expression status (negative vs. positive), HER2 (human 
epidermal receptor 2) overexpression/amplification status 
(overexpression/amplification vs. no overexpression/amplification), adjuvant 
chemotherapy, adjuvant hormonal therapy, neoadjuvant therapy (if applicable) and 
age at diagnosis (≤54 vs. ≥55 years) in the training (A), internal validation (B) and 
external validation (C) cohorts. Solid squares represent the hazard ratio (HR) of 
recurrence and open-ended horizontal lines represent the 95% confidence intervals 
(CIs). All p values were calculated using Cox proportional hazards analysis and p < 
0.05 was considered a statistical significant p value. AC: Anthracycline, T: Taxane, 
AC-T: Anthracycline and Taxane. 
 
Supplementary Figure S3: Receiver operating characteristic (ROC) analysis of 
Nottingham clinico-pathological response index (NPRI) score and other clinico-
pathological covariates were performed for predicting breast cancer specific survival  
in the training (A), internal validation (B) and external validation (C) cohorts.    The 
area under the curve (AUC) was calculated for ROC curves, and sensitivity and 
specificity was calculated to assess the performance of residual cancer burden 
(RCB) alone (1), NPRI alone (2), and * a statistical prognostic model that constructed 
based on multivariable Cox proportional hazards incorporating known clinico-
pathological prognostic variables including: pathological complete response (pCR), 
RCB score, presenting clinical TNM (Tumour, Node and Metastases) stage, revised 
pathological TNM stage (yp-TNM) stage, histological grade based on Nottingham 
grading system, ER (oestrogen receptor) expression status, HER2 (human 
epidermal receptor-2) status, and age at diagnosis (3). ** ROC analysis was also 
performed for the aforementioned prognostic model after incorporating the NPRI 
score (4).  Dashed grey lines indicate the 45º angle tangent line marked at a point 
that provides best discrimination between true positives and false positives, 
assuming that false positives and false negatives have similar costs. AC: 
Anthracycline, T: Taxane, AC-T: Anthracycline and Taxane. 
 
